A note from the author. This essay is written from the terrain paradigm. Disease is the body’s response to dietary, toxic, electromagnetic, and psychological insult. Microorganisms and blood clots appear at sites of tissue breakdown rather than cause it. Within conventional cardiology’s plaque-theory framework, the twelve practices that follow are standard clinical care. From the terrain side, they are deceptions. Two registers operate here. When the essay engages material framed in establishment terms (ejection fraction, atherosclerosis, autoimmune arteritis, the “immune” system, genetic susceptibility, vitamins as discrete nutrients), the establishment vocabulary appears in quotation, attribution, and reference titles. The terrain paradigm operates in the author’s own analytical voice. Readers who have not made the shift from germ theory and mechanistic biology to terrain may find the conclusions inverted from what they expect.
What Was Done to Kilmer McCully
In 1968, Kilmer McCully, an assistant professor of pathology at Harvard Medical School, examined tissue from an eight-year-old boy who had died of a stroke. The child had homocystinuria, a metabolic condition producing massive elevations of the amino acid homocysteine. His coronary arteries looked like those of an elderly man with advanced atherosclerosis. His cholesterol level was normal.⁴
McCully had seen tissue like this before, from a two-month-old infant with the same condition. Two children with arteries destroyed by an amino acid the medical literature had barely discussed. His 1969 paper in the American Journal of Pathology proposed a mechanism. Elevated homocysteine damages the endothelium directly, generates free radicals in the arterial wall, impairs the production of nitric oxide, and promotes clotting. The biochemical cofactors that clear homocysteine (folate, B6, B12) are systematically stripped from the industrial food supply. Restore the cofactors, clear the homocysteine, protect the artery. The proposal was simple, testable, and cheap.
Harvard’s response was not scientific rebuttal. Harvard denied him tenure. Massachusetts General Hospital, where he held a joint appointment, moved his laboratory to the basement. His research funding evaporated. He was told his work was “not of sufficient interest” to the institution. For two years no medical institution would hire him. Colleagues who had praised his work stopped returning his calls. He eventually secured a position at the Veterans Administration hospital in Providence, Rhode Island, and continued his research quietly, publishing steadily, waiting for the profession to catch up.⁴ He is now in his nineties. The mechanism he identified is beyond dispute. The test he proposed is still not part of routine cardiology practice.
What was done to McCully in the early 1970s was not a mistake. It was a structural response. The mechanism he found could not be commercialized. B vitamins are cheap and unpatentable. Statins were about to be launched and would generate over a trillion dollars in sales. A profession whose training, income, and institutional standing depended on the cholesterol hypothesis had to choose between the man and the market. It chose the market. Every subsequent choice the specialty has made about what to test, what to prescribe, and what to teach has followed the same structural logic.
An interventional cardiologist earns between $500,000 and $1,000,000 annually, most of it from procedures performed in the cath lab.¹ Hospitals depend on cardiac procedure revenue. Device manufacturers spend billions marketing their products to the specialists who implant them. The ACC/AHA guidelines that govern clinical decisions are written by committees dominated by members with financial ties to the drug and device companies whose products the guidelines recommend. When the 2004 National Cholesterol Education Program guidelines lowered LDL targets in a way that would put millions of additional Americans on statins, most panel members had undisclosed pharmaceutical ties. The Washington Post reported the conflicts. Critics demanded disclosure. The guidelines were not changed.²
The specialty’s foundational hypothesis was itself a selection artifact. Ancel Keys had data available for twenty-two countries when he published his 1953 graph correlating fat consumption with heart disease mortality. He selected six that fit his hypothesis. When the full twenty-two were subsequently analyzed by Yerushalmy and Hilleboe in 1957, the correlation vanished.³ The diet-heart hypothesis that emerged from Keys’ selection became the framework for the entire preventive apparatus of American cardiology, its dietary guidelines, its diagnostic categories, and its drug portfolio.
What follows are twelve specific things the specialty has decided not to say. Each is documented in the specialty’s own trials, its own registries, or its own admissions. What the twelve share is a common cause: the profession’s incentive structure selects for what generates procedures and prescriptions, and against what threatens them. McCully’s story is the pattern. The twelve items are its effects.
This work stays free because paid subscribers make it possible. They get the full book library, the Deep Dive Audio Library, and the Questions for Your Doctor, Before You Consent, and Package Insert series. No grants, no gatekeepers — your subscription is what keeps it that way.
Two More Buried Figures
McCully was not the only researcher whose work threatened cardiology’s foundations. Two others deserve mention because their work is drawn on throughout what follows.
Uffe Ravnskov (1934–2023), Danish physician and independent researcher, published The Cholesterol Myths in 1991 in Sweden and in 2000 in English. The book documented, with citations to the primary literature, the fraudulent foundation of the diet-heart hypothesis. During a live Swedish television broadcast in 1992, a copy of the book was burned on air.⁵ Ravnskov co-founded The International Network of Cholesterol Skeptics. Their 2016 systematic review in BMJ Open, finding that high LDL was inversely associated with mortality in people over sixty, was the most-read article on the journal for six consecutive months. Their 2018 review in Expert Review of Clinical Pharmacology became the second-most-downloaded paper from Taylor and Francis.⁶ Statin prescribing continued to rise.
Thomas Cowan (born 1957), American physician, spent forty years reframing the organ itself. His Human Heart, Cosmic Heart (2016) makes the case that the heart’s primary function is to organize vortex patterns in blood flow, rather than to generate the pressure that pushes blood through the vessels. Blood moves via the properties of structured water lining the endothelium, described by Gerald Pollack’s laboratory work at the University of Washington.⁷ Cowan also preserved knowledge of strophanthus in English after German cardiology abandoned it. His framework will surface at Items 11 and 12.
Malcolm Kendrick, the Scottish general practitioner whose two books on the cholesterol hypothesis and the thrombogenic alternative anchor much of the evidence in what follows, provides the master documentation across the twelve items.
1. Cholesterol does not cause heart disease.
The teaching: elevated LDL causes atherosclerosis. Lowering it prevents heart attacks and strokes. Statins are the primary tool. Prescribe widely.
The specialty’s own longest-running study contains the confession. The Framingham Heart Study, launched in 1948 and specifically designed to establish the cholesterol-heart-disease link, published its thirty-year data with a finding buried in the report. For each 1 mg/dl drop in cholesterol, there was an 11 percent increase in coronary and total mortality.⁹ People whose cholesterol fell over the follow-up period died at higher rates than those whose cholesterol rose. William Castelli, former director of Framingham, admitted publicly that in Framingham, the more saturated fat and cholesterol a person ate, the more calories a person ate, the lower their serum cholesterol.⁹ The Multiple Risk Factor Intervention Trial, following 361,662 men, found that those with cholesterol below 170 mg/dl had double the death rate from cerebral hemorrhage compared to those with higher levels. Below 160, the death rate quadrupled.¹⁰
The most damning fact requires no biostatistics to state. Most people who have heart attacks do not have elevated LDL. Most people who have elevated LDL do not have heart attacks.¹¹ A causal agent absent from most cases and present without effect in most other cases is a marker of something else, or of nothing at all.
Merck knew. Statins block HMG-CoA reductase, an enzyme in the mevalonate pathway that produces both cholesterol and coenzyme Q10. The two share a biosynthetic route. Q10 is the primary electron carrier in the mitochondrial respiratory chain. The heart, the organ with the highest energy demand in the body, contains the highest concentration of Q10 in the body.¹² Statins deplete plasma Q10 by 16 to 54 percent.¹³ Before launching lovastatin, Merck filed two patents in 1990 for combinations of their statin with Q10 supplementation. US Patent 4,929,437 and US Patent 4,933,165. The second patent named Nobel laureate Michael S. Brown as inventor. Its stated rationale: “since CoQ10 is of benefit in congestive heart failure patients, the combination with HMG-CoA reductase inhibitors should be of value in such patients who also have added risk of high cholesterol levels.”¹⁴ Neither combination was ever marketed. Kendrick asked the operative question: could statins be totally innocent if they required a built-in antidote?¹⁵
For the full development of the cholesterol argument, see The Wrong Enemy and Cholesterol and Statins: An Essay on the Most Successful Unfalsifiable Claim in Medicine.
2. Stents do not prevent heart attacks in stable disease.
Roughly a million stents are placed in the United States annually, at about $30,000 per procedure. The rationale offered to patients is that opening a narrowed artery prevents the heart attack the narrowing would otherwise cause.
The COURAGE trial, published in the New England Journal of Medicine in 2007, randomized 2,287 patients with stable coronary disease to stenting plus optimal medical therapy or to optimal medical therapy alone. Follow-up averaged 4.6 years. No difference in death or myocardial infarction between the two groups.¹⁶ The ORBITA trial, published in The Lancet in 2017, went further. It used a sham-controlled design in which some patients received a real stent and others received a simulated procedure without a stent placed. Neither the patients nor the assessing physicians knew who had received which. The primary endpoint was exercise time. There was no difference. Sham stenting produced the same result as real stenting.¹⁷ The ISCHEMIA trial, published in the New England Journal of Medicine in 2019, tested an invasive strategy (angiography followed by revascularization) against conservative medical management in 5,179 patients with moderate to severe ischemia. No mortality benefit. No reduction in myocardial infarction.¹⁸
Three trials in the specialty’s own flagship journals. Nothing changed in practice. Stent placement did not decline. The revenue continued.
3. Bypass surgery does not extend life for most patients who receive it.
Approximately 400,000 coronary artery bypass grafting procedures are performed in the United States annually, at roughly $100,000 each. Surgical mortality is 1 to 2 percent from the procedure itself.
The Coronary Artery Surgery Study, the VA Cooperative Study, and the European Coronary Surgery Study collectively established in the 1970s and 1980s that bypass surgery extends life only in the narrow subgroup of patients with left main coronary disease or three-vessel disease with impaired left ventricular function. For everyone else, which is most patients who undergo the procedure, no mortality advantage over medical management.¹⁹ The MASS-II trial, published in Circulation in 2010, compared bypass surgery to medical therapy in stable multi-vessel disease over ten years of follow-up. No difference in overall mortality.²⁰ Vein grafts harvested from the leg develop atherosclerosis faster than the native coronary arteries they were meant to replace. Many patients need repeat procedures.
4. The artery they open is rarely the artery that later kills you.
Coronary angiography identifies the biggest visible narrowings. The specialty then treats the biggest narrowings on the assumption that the biggest are the most dangerous.
Autopsy studies contradict the assumption. Giorgio Baroldi, the Italian pathologist whose autopsies of heart attack victims Cowan cites, found that 80 percent of people dying of a heart attack showed no arterial blockage sufficient to explain the event.²¹ Many had extensive stable plaques compensated by collateral circulation and had lived symptom-free for years. Others died from vessels the angiogram would have called minor. Vulnerable plaques, the ones most likely to rupture and produce the acute event, tend to be small, non-obstructive, and invisible on angiography. Large stable plaques calcify and reinforce themselves. Coronary calcium scores, marketed as advanced screening, measure the healed plaques rather than the dangerous ones and correlate with lower heart attack risk, not higher.²³
Angiography is also less reliable than the specialty presents it as. Different cardiologists reading the same angiogram reach different conclusions on the significance of a given lesion 30 to 40 percent of the time.²² A two-dimensional shadow of a three-dimensional structure viewed from a single angle can look like a 50 percent stenosis or a 90 percent stenosis depending on which projection is chosen. The specialty’s most confident intervention rests on the least reliable diagnostic image in cardiology.
5. Blood pressure targets keep dropping to sell more drugs.
The threshold for hypertension has moved down repeatedly across the specialty’s history. 160/95 became 140/90. 140/90 became 130/80. The 2017 ACC/AHA guidelines lowered it again, capturing roughly thirty million additional Americans into a new drug-eligible category overnight.
The trial that drove the last drop was SPRINT, published in the New England Journal of Medicine in 2015. SPRINT compared intensive blood pressure control (systolic target below 120) to standard control (target below 140) in 9,361 patients. The trial excluded diabetics, who had been studied separately in the ACCORD trial with a negative result the guidelines then ignored. SPRINT used automated unattended blood pressure measurement, which reads approximately 10 mmHg lower than standard office measurement, so patients meeting the “120” threshold in the trial were actually running closer to 130 by conventional office readings. The trial was stopped early on the basis of interim analysis, a technique known to inflate apparent effect size.²⁴ Cochrane reviews of tight blood pressure control in the elderly have not found mortality benefit and have documented increased falls, kidney injury, and syncope.²⁵
Each guideline revision brings in millions of patients who were told the previous year that their numbers were fine.
6. Saturated fat was rehabilitated by the specialty’s own meta-analyses.
For fifty years the specialty told the population that saturated fat causes heart disease. The advice reshaped the food supply. Households pulled butter and lard from their cupboards; institutional cafeterias substituted margarine and vegetable oil.
The specialty’s own meta-analyses have overturned the advice. Siri-Tarino in 2010, pooling twenty-one prospective studies covering 347,747 subjects, found no association between saturated fat intake and cardiovascular disease.²⁶ Chowdhury in 2014, pooling seventy-two studies covering over six hundred thousand subjects, found the same.²⁷ De Souza in 2015, pooling seventy-three studies, found no association between saturated fat and total mortality, cardiovascular mortality, coronary disease, or ischemic stroke.²⁸ Three large meta-analyses in the mainstream cardiovascular literature. The specialty’s dietary advice has not been updated.
The intervention trials tell a sharper story. The Sydney Diet Heart Study, run from 1966 to 1973, replaced saturated fat with vegetable oil in the treatment group. The full data was buried until Christopher Ramsden, working at the National Institutes of Health, recovered it and reanalyzed it in 2013. The men who replaced saturated fat with vegetable oil had a 62 percent higher death rate.²⁹ The Minnesota Coronary Survey, hidden for four decades and recovered by Ramsden’s team in 2016, showed that for every 30 mg/dl reduction in cholesterol in the treatment group, mortality increased by 22 percent.³⁰ Teicholz’s The Big Fat Surprise documents the institutional history of how the advice came to be given despite the evidence that contradicted it.³¹
7. Salt restriction raises mortality in most people.
The teaching is that salt raises blood pressure, blood pressure causes heart disease, therefore restrict salt. The specialty targets 2,300 mg of sodium per day for the general population and 1,500 mg for anyone with hypertension or over the age of fifty.
James DiNicolantonio, cardiovascular researcher and author of The Salt Fix, has assembled the data the guidelines do not cite. About 80 percent of people with normal blood pressure are salt-insensitive, meaning their blood pressure does not rise with increased salt intake. Among those with prehypertension, roughly 75 percent are insensitive. Even among those diagnosed with hypertension, about 55 percent are insensitive.³² The optimal sodium intake range for healthy adults sits between 3 and 6 grams per day, well above the guideline target. The relationship between sodium intake and cardiovascular mortality follows a J-curve. The lowest sodium intake groups, which is to say those meeting or beating the guideline target, have the highest cardiovascular and all-cause mortality. The PURE study, following 101,945 people across seventeen countries, confirmed the pattern.³³
The Korean paradox. Koreans consume among the highest sodium intakes in the world, over 4,000 mg per day. They have one of the world’s lowest rates of hypertension and cardiovascular disease.³² Low-salt diets increase heart rate, activate the renin-angiotensin-aldosterone system the antihypertensive drugs are designed to block, contribute to insulin resistance, and elevate the risk of hyponatremia in the elderly.³² The advice to restrict salt is not supported by the evidence used to give it.
8. Ancel Keys built the diet-heart hypothesis by discarding data.
The 1953 graph. Six countries on a straight line. Fat consumption on one axis, heart disease mortality on the other. Elegant. Persuasive. The image on which the entire diet-heart hypothesis was constructed.
The countries not shown. Data was available for twenty-two nations at the time Keys drew his graph. He selected the six that fit his hypothesis. When Jacob Yerushalmy and Herman Hilleboe reanalyzed the full twenty-two-country dataset in 1957, publishing in the New York State Journal of Medicine, the correlation vanished. Countries with similar fat intakes had heart disease rates that varied by factors of three and four. Keys’ clean line was an artifact of his selection.³ Kendrick performed a version of the same exercise using the seven European countries with the lowest saturated fat intake and the seven with the highest. The high-fat countries had lower heart disease rates. Every one of them.¹¹
Even within Keys’ own selected data, the internal inconsistencies were visible. In Finland, the region of Karelia had five times the coronary mortality of Turku despite nearly identical cholesterol levels. On the Greek islands, Corfu had five times the cardiac deaths of Crete despite lower cholesterol.¹¹
The Sugar Research Foundation, faced with emerging evidence linking sucrose to coronary disease in the 1960s, paid Harvard researchers the equivalent of $50,000 in today’s money to write a review attacking the sugar research and promoting the fat hypothesis instead. The researchers assured the sugar industry that they were “well aware of your particular interest” and would “cover this as well as we can.” The review appeared in the New England Journal of Medicine in 1967 without disclosure of the funding source. The documents establishing the payment and the intent surfaced decades later in the archives of Cristin Kearns and were published in JAMA Internal Medicine in 2016.³⁴
The specialty’s founding hypothesis is a selection artifact underwritten by a documented industry payment. Its diagnostic categories, dietary guidelines, and drug portfolio all descend from this base.
9. Homocysteine, and the test the specialty still refuses to run.
Cardiologists do not routinely test homocysteine. It is not in the ACC/AHA lipid panel. Most insurance plans do not cover it. Most patients have never heard of it. Fifty years after McCully identified the mechanism, the specialty’s silence on the topic is the loudest ongoing indictment in this list.
The observational data assembled in the interval has been consistent. The Framingham data showed that people with the highest homocysteine levels had twice the heart disease risk of those with the lowest.³⁵ The European Concerted Action Project showed that elevated homocysteine increased heart disease risk by 200 percent.³⁶ The Nurses’ Health Study, following over 80,000 women, found that those with the highest folate and B6 intake had 45 percent less heart disease than those with the lowest, an effect independent of other risk factors.³⁷
The randomized trials of B-vitamin supplementation for cardiovascular events have been mixed. HOPE-2 in 2006 gave folic acid, B6, and B12 to 5,522 patients with vascular disease and reduced stroke by 25 percent as a secondary endpoint, though the composite primary endpoint did not reach significance.³⁸ NORVIT and VISP were negative for the composite endpoint.³⁹ The subsequent debate has largely been about whether the trials used the right forms (folic acid, which requires enzymatic conversion, rather than methylfolate, which does not) and the right populations (patients already on statins and aspirin whose damage patterns may mask the intervention).⁴⁰ The observational marker data has not been meaningfully disturbed. Cardiology’s response to the marker has been to ignore it in daily practice.
The compounds involved (folate, methylcobalamin, pyridoxal-5-phosphate) are the biochemical cofactors the methylation cycle requires to clear homocysteine. They are present in whole foods (organ meats, eggs, leafy greens, legumes) and stripped from processed foods. White flour has 90 percent of its B6 removed in processing. A diet of industrial food combined with clinical silence on homocysteine testing produces the endothelial injury the specialty then treats with drugs that address neither the cofactor depletion nor the mechanism.
For the fully worked case on the homocysteine mechanism, see The Wrong Enemy.
10. The teeth and the heart are the same problem.
The teaching is silence. Cardiologists do not ask about dental history. Periodontal disease is a problem for the dentist, not the internist. Root canals are considered dental infrastructure with no bearing on cardiac risk. The specialty separated the mouth from the heart around 1950, when the American Dental Association reversed the focal-infection position it had held since the 1920s.
Weston Price, the founding director of the American Dental Association’s research section and its chairman from 1914 to 1928, spent twenty-five years documenting the systemic effects of root-canal-treated teeth. He worked with a sixty-person research team and over five thousand animals. He extracted root-filled teeth from patients with specific systemic diseases and implanted fragments under the skin of rabbits. Rabbits inoculated from patients with heart disease developed heart disease. Rabbits inoculated from patients with kidney disease developed kidney disease. In one endocarditis case, cultures from a fifteen-year-old’s infected molar were injected into thirty rabbits. Twenty-eight died of endocarditis. Ground root-canaled teeth were then sterilized to remove all bacteria and injected in minute quantities. The rabbits still developed heart disease and died. The toxins produced by the anaerobic organisms colonizing the dead tooth were more potent than the organisms themselves.⁴¹ Price’s own son had died of a heart attack shortly after Price performed a root canal on him. That was the research’s origin.
The modern data confirms the pattern. Willershausen and colleagues, publishing in the Journal of Endodontics in 2009, compared 125 patients hospitalized with acute myocardial infarction to matched controls and found significantly higher rates of chronic endodontic infection in the infarction group.⁴² Larger observational studies have found that endotoxemia from periodontal disease and root canals correlates with cardiovascular events more tightly than cholesterol does.⁴³ A textbook of periodontal medicine states that the evidence is “strong enough to establish oral infections as an independent risk factor for CVD.”⁴⁴
The cardiologist does not ask about the dentist. The dentist does not ask about the cardiologist. Two specialties treating the same disease from opposite ends of the same organism, neither acknowledging the other.
For the extended treatment of the dental side of this problem, see 12 Things Your Dentist Was Trained Not to Tell You.
11. Ejection fraction measures a function the heart does not primarily perform.
Ejection fraction is the master metric of modern cardiology. The percentage of blood in the left ventricle expelled with each beat. Normal is 55 to 70 percent. Below 40 percent is called “reduced” and triggers escalating pharmaceutical intervention. Below 35 percent is the threshold for implantable defibrillator placement, a device costing $50,000 to $100,000 with ongoing surveillance costs. Below 20 percent puts a patient on the transplant list. The number governs decisions about defibrillators, transplants, drugs, prognosis, and the conversation the cardiologist has with the family.
The number measures the volume percentage expelled per beat under the founding assumption that the heart is a pressure-propulsion pump and that the ejection percentage is a meaningful index of that function. As a pressure-propulsion pump, the heart is only about 30 percent efficient. Leon Manteuffel-Szoege, working in Warsaw in the 1940s, demonstrated that blood continues to circulate for up to two hours after the heart stops, and concluded that blood has its “own motor energy” independent of cardiac contraction.⁴⁵ Blood begins flowing in the developing embryo before the heart has formed. Rivers of blood move through primitive vessels while what will become the heart is still an unstructured cluster of cells.⁴⁶ These are not observations the pump model can accommodate.
The specialty’s own diagnostic category called heart failure with preserved ejection fraction (HFpEF) makes the case for the metric’s inadequacy on the specialty’s own terms. HFpEF now constitutes more than half of all heart failure cases. The heart contracts normally. The ejection fraction is preserved, sitting in the 55 to 70 percent range. And the patient is still dying. Every major trial of the cardiovascular drug classes the specialty had built its practice on, applied to HFpEF, has failed to reach its primary endpoint. CHARM-Preserved with candesartan (3,023 patients). PEP-CHF with perindopril (850 patients). I-PRESERVE with irbesartan (4,128 patients, death rates essentially identical between drug and placebo at 52.6 versus 52.3 per 1,000 person-years). TOPCAT with spironolactone (3,445 patients).⁴⁷ The 2023 JACC Heart Failure Scientific Statement conceded that “the pathophysiologic mechanisms driving HF progression in HFpEF remain poorly understood.”⁴⁸ Two SGLT2 inhibitors imported from diabetes practice have shown modest reductions in heart-failure hospitalizations in HFpEF through mechanisms that are still debated, without clear all-cause mortality benefit. What has not appeared inside the pump-model framework is a drug that fixes the physiology the ejection fraction claims to measure.
Peter Langsjoen’s 2019 study demonstrates what happens when the actual cause is addressed. 142 heart failure patients with mean 6.8 years of statin exposure. 94 percent had HFpEF. Treatment protocol: stop the statin, start Q10 at 300 mg per day. NYHA Class I improved from 8 percent to 79 percent. In the subgroup with reduced ejection fraction, mean EF improved from 35 percent to 47 percent. One-year mortality: zero. Three-year mortality: 3 percent.⁴⁹ The metric moves when the treatment addresses the actual injury. The Q-SYMBIO trial confirmed the direction with 420 patients across 17 centers, randomized placebo-controlled: Q10 halved cardiovascular mortality over two years. Number needed to treat to prevent one death: ten.⁵⁰
The metric governs decisions the specialty cannot justify from the physiology. A cheap unpatentable molecule outperforms every major HFpEF drug trial in the specialty’s literature and has not entered guideline care.
For the fully worked case, see Congestive Heart Failure: The Modern Beriberi.
12. The heart is not a pump.
The teaching is old and universal. The heart is a muscular pump that pushes blood through roughly 60,000 miles of vessels. Every downstream intervention on this list, from the drugs that support contractility to the mechanical devices that assist it to the transplants that replace the organ altogether, sits inside this frame.
The mathematics do not close. The heart weighs about 300 grams. The vascular network it supplies extends across sixty thousand miles of vessels. Most of that network is capillaries, so narrow that red blood cells must deform and pass through single file. The pressure required to push blood through this network against the documented resistance exceeds by orders of magnitude what a 300-gram organ could produce. Athletes increase cardiac output by 600 percent during intense exercise. The heart muscle mass does not multiply sixfold in the process. The energy available does not multiply sixfold. Blood continues moving through capillaries even in tissue surgically isolated from cardiac pressure.
The alternative comes from Gerald Pollack’s laboratory at the University of Washington. Pollack demonstrated that water adjacent to hydrophilic surfaces (which include the interior walls of blood vessels) forms a structured layer, distinct from bulk water in liquid or solid phase, that he named the fourth phase of water. This layer carries a negative charge, excludes solutes, and grows when the surface is illuminated by infrared light. In tubes, it generates flow without any pumping. The mechanism can be replicated on a bench.⁵¹ Applied to the vasculature, the model gives blood its own motor. The negatively charged exclusion zone lining the vessel walls repels the negatively charged red blood cells, propelling them along the vessel.
The heart’s actual function, on this model, is to organize the flow into specific vortex patterns. Frank Chester discovered that a specific seven-sided geometric figure, which he named the chestahedron, sits at exactly 36 degrees when nested inside a cube. This is precisely the angle of the heart in the chest. When the chestahedron is spun in water, it generates vortex patterns that match those seen in echocardiograms of the ventricles.⁷ Francisco Torrent-Guasp, working over several decades in Spain, demonstrated that the ventricular muscle fibers form a helical spiral, wrapping around themselves in a figure-eight pattern.⁵² That arrangement is far more complex than a pump wall would need to be, and is exactly what vortex generation would require.
Blood begins flowing in the developing embryo before the heart forms. Rivers of blood move through primitive vessels via the properties of structured water in those vessels, weeks before there is a heart to pump them. When the heart forms, it forms at a bend in an already-flowing stream, the way a hydraulic ram is inserted into an existing river.⁴⁶
What the specialty calls heart failure is not, on this model, primarily pump failure. It is systemic energy deficit, autonomic dysregulation, and the failure of structured water dynamics in the vasculature. The interventions cardiology performs (drugs to force the pump to work harder, mechanical devices to assist pumping, transplants to replace the pump) are all built on a model that misidentifies the organ’s primary function.
The buried medicine confirms the model by working through it. Strophanthus, a cardiac glycoside derived from the seeds of an East African vine, was used in German cardiology for over fifty years for angina, heart failure, and prevention of heart attacks. Coal miners in 1970s Germany died at approximately thirty per year of heart attacks in a workforce of 1,800. After the introduction of strophanthus extract, deaths dropped to two per year. Professor Kern documented the 93 percent reduction.⁵³ A Berlin hospital’s twelve-year series reported that 99 percent of chest pain patients became complaint-free within two weeks on oral strophanthus. A survey of practicing German physicians found that 98 percent reported high effectiveness. The remaining 2 percent described it as “within limits positive.” Not one physician reported negative assessment.⁵³ The mechanism operates through Gilbert Ling’s cellular framework, in which the sodium-potassium pump the specialty was taught to believe in mathematically cannot exist. Ling calculated that the pump would require thirty times more ATP than cells actually produce.⁸ Cells maintain the sodium-potassium distribution through the structure of intracellular water, which forms a gel that geometrically excludes sodium while accommodating potassium. Ouabain, the active compound in strophanthus, supports the formation of that gel.
Strophanthus disappeared from mainstream medicine in the 1970s. Digoxin, the other cardiac glycoside in use, remained. Digoxin is fat-soluble, accumulates in tissue, has a narrow therapeutic window, causes roughly eight thousand US hospital visits annually for toxicity, and produced no mortality benefit in the DIG trial.⁵⁴ The safer medicine, requiring less monitoring, disappeared. The dangerous one, requiring continuous physician supervision and blood tests, survived.
For the extended treatment of the strophanthus story and the cellular biology beneath it, see The Gift from Paradise: Strophanthus and the Heart Medicine That Disappeared, and my summary of Human Heart, Cosmic Heart.
The Cardiologist’s Waiting Room
The next appointment is on the calendar. You have not canceled it. It is Tuesday at 3:15.
You will sit down. The nurse will take your blood pressure. A phlebotomist will draw blood for a lipid panel. Twelve electrodes will go on your chest, wrists, and ankles for the ECG. The cardiologist will study the numbers, find something above threshold, present a treatment plan. You will schedule the next appointment, pick up the prescription, and come back in six months.
Nothing in the sequence will ask about the six years of grief since your husband died, about the antidepressants you were put on after that, about the electrical hum in the house since the smart meter was installed, about the sixteen root canals in your extended family, about the decades of industrial food that stripped the cofactors from your methylation cycle before the homocysteine that will not be tested for climbed to whatever it is now. None of it will be asked because the visit is not structured to ask it.
Cardiology in its current form is a repair industry positioned at the end of a long causal chain. The chain begins in the kitchen, the workplace, the bedroom, the electromagnetic environment, the dentist’s chair, the medicine cabinet, and the accumulated psychological weight the patient carries into the six-month appointment. A cardiology that addressed those upstream causes would be a smaller cardiology, less remunerative, with fewer specialists. The market did not select for that cardiology. The insurance codes do not pay for the diet conversation, the stress conversation, the dental conversation, the medication-review conversation.
The knowledge exists. McCully documented the mechanism in 1969. Ravnskov dismantled the diet-heart hypothesis across three decades of publication. Cowan reframed the organ itself. Kendrick assembled the evidence into two books that any interested reader can obtain. The work was done, and published, and translated into English, and left there. It has been the specialty’s choice not to integrate it.
What remains is the redirected gaze. Toward the food on the table. Toward the water in the glass. Toward the sunlight, the ground, the sleep, the community. Toward the dentist who will remove the root canal that has been leaking anaerobic toxins into the systemic circulation for twenty years. Toward the electromagnetic environment that no cardiologist has ever asked about. Toward strophanthus, still available from a small number of practitioners, still working through the mechanism the specialty walked away from, still ignored.
You will go to the appointment on Tuesday. You will ask the questions the appointment is not structured to handle. What the cardiologist says, or does not say, is the diagnostic finding you take home.
What This Means for the Next Appointment
Before any statin prescription, ask for the absolute risk reduction and the number needed to treat, not the relative risk reduction the promotional materials use. The two numbers can differ by a factor of thirty.
Before any stent recommendation for stable disease, ask about the COURAGE trial and the ORBITA trial by name. The cardiologist knows what they are.
Before any bypass for stable disease, ask about MASS-II.
Before accepting an ejection fraction as a prognosis, ask about the Langsjoen 2019 study and whether Q10 depletion by statins might have contributed to the number.
Ask what homocysteine testing shows. If it has not been performed, ask why not.
Ask whether the specialist has read McCully’s The Heart Revolution, Kendrick’s The Great Cholesterol Con, Ravnskov’s The Cholesterol Myths, or Cowan’s Human Heart, Cosmic Heart. The answer, or the manner of the answer, will tell you what to do next.
Ask about the dentist. Ask what percentage of your teeth are root-canaled or crowned. Ask whether the cardiologist has ever asked a patient about their dentist. If the answer is no, ask why not.
A cardiologist who has read the sources will not be threatened by the questions. One who has not will treat them as obstruction, as internet misinformation, or as denialism. Either response is useful information. The appointment has shifted from a procedure being done to a procedure being negotiated.
For patients already deep in the cascade, on the statin for the third decade, with the stent placed or the bypass performed, told the ejection fraction leaves them with a limited window: the terrain is still upstream. Reversible cardiomyopathy is a recognized category in the specialty’s own literature. Alcoholic cardiomyopathy resolves in 42 percent of cases with abstinence. Tachycardia-induced cardiomyopathy normalizes with rate control. What made the damage produced the damage. Removing what made the damage removes some fraction of the damage.
How to Explain It to a Six-Year-Old
Your heart is like the gardener at the center of a big garden. The gardener does not water every plant one by one. That would be impossible, because the garden is huge and the gardener is small. What the gardener does is stir the water in the pond into a special swirling pattern. The swirling pattern makes the water move through all the little channels in the garden by itself. Every plant gets watered because the swirl keeps going.
The doctors who take care of hearts do not know about the swirl. They were taught in school that the gardener pushes the water through the channels by squeezing very hard. So when the plants start to droop, the doctors give the gardener drugs to make him squeeze harder, or they put in mechanical arms to help him squeeze, or they cut open the channels and put in metal tubes to help the water get through the tight spots. None of it works very well. The plants keep drooping. The gardener gets tired.
What is actually happening is that the water in the garden has stopped swirling properly, because too many bad things have gotten into the garden and messed up the swirl. Bad food. Bad water. Bad worry that never stops. Bad electric humming from the machines everywhere. Bad teeth that are leaking poison into the pond. When you fix those upstream things, the swirl comes back. The plants stop drooping. The water starts flowing through the little channels by itself again.
Once, a long time ago, doctors in Germany used a special medicine that helped the swirl. It came from a plant that grows in Africa. Most heart doctors today have never heard of it. The heart is a gardener. The pump is the story the doctors were taught. The swirl is what actually keeps you alive.
In Print
Seven of my books are now available as paperbacks, printed to order through Lulu and shipped worldwide. The Unvaccinated lays out the completely unvaccinated as a comparison group across twenty chapters and five appendices — as far as I know, the only book of its kind. Medicalized Motherhood follows a woman through 123 documented interventions from teenage pill to postpartum discharge. Drilling for Profit argues that cavities, gum disease, and crooked teeth are a dietary problem the dental profession treats surgically. What Your Vet Can’t Tell You applies the same critique to pets — food, vaccines, and a profession trained by the industries whose products cause the harm. Escape from Psychiatry documents the fabrication of the DSM, the collapse of the serotonin hypothesis, and the specific damage done by every major psychiatric drug class.
Two more take up what the first five leave out — the remedies the first five explain why you need. The DMSO Book covers 100,000 studies, zero deaths, and one approval — the suppressed science of medicine’s most versatile compound. Chlorine Dioxide: The Forbidden Remedy collects the interviews, protocols, and evidence from the doctors and researchers they tried to silence.
A physical book reaches the person a Substack post never will — the sceptical relative, the friend who won’t click a link but might open a book, the visitor whose eye lands on a coffee table. Buy one to keep, and one to give away.
New Biology Clinic
For those of you looking for practitioners who actually understand terrain medicine and the principles we explore here, I want to share something valuable. Dr. Tom Cowan—whose books and podcasts have shaped much of my own thinking about health—has created the New Biology Clinic, a virtual practice staffed by wellness specialists who operate from the same foundational understanding. This isn’t about symptom suppression or the conventional model. It’s about personalized guidance rooted in how living systems actually work. The clinic offers individual and family memberships that include not just private consults, but group sessions covering movement, nutrition, breathwork, biofield tuning, and more. Everything is virtual, making it accessible wherever you are. If you’ve been searching for practitioners who won’t look at you blankly when you mention structured water or the importance of the extracellular matrix, this is worth exploring. Use discount code “Unbekoming” to get $100 off the member activation fee. You can learn more and sign up at newbiologyclinic.com
References
Interventional cardiologist compensation data, MGMA Physician Compensation Survey, and Medscape Cardiologist Compensation Report 2023.
Washington Post, “Statins Committee Members Had Ties to Drug Firms,” October 15, 2004, documenting undisclosed pharmaceutical ties among National Cholesterol Education Program panel members. See also Malcolm Kendrick, The Great Cholesterol Con: The Truth About What Really Causes Heart Disease and How to Avoid It (London: John Blake Publishing, 2008).
Yerushalmy, J. and Hilleboe, H.E. “Fat in the Diet and Mortality from Heart Disease: A Methodologic Note.” New York State Journal of Medicine 57 (1957): 2343–2354.
Kilmer S. McCully, The Heart Revolution: The Extraordinary Discovery That Finally Laid the Cholesterol Myth to Rest (New York: HarperPerennial, 1999). McCully’s original paper: McCully KS, “Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis,” American Journal of Pathology 56 (1969): 111–128.
Uffe Ravnskov, The Cholesterol Myths: Exposing the Fallacy That Saturated Fat and Cholesterol Cause Heart Disease (Washington, DC: NewTrends Publishing, 2000). The book burning incident on Swedish television is documented in Ravnskov’s public writings and in various profiles of THINCS.
Ravnskov U et al., “Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review,” BMJ Open 6 (2016): e010401. Ravnskov U et al., “LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature,” Expert Review of Clinical Pharmacology 11 (2018): 959–970.
Thomas Cowan, Human Heart, Cosmic Heart: A Doctor’s Quest to Understand, Treat, and Prevent Cardiovascular Disease (White River Junction, VT: Chelsea Green Publishing, 2016).
Gilbert Ling, Life at the Cell and Below-Cell Level (New York: Pacific Press, 2001), and Gilbert Ling, A Revolution in the Physiology of the Living Cell (Malabar, FL: Krieger Publishing, 1992). Ling’s calculations of the ATP requirement for the sodium-potassium pump and his stripped-membrane experiments are summarized in Cowan, Human Heart, Cosmic Heart, and in the strophanthus literature at newbiologyclinic.com.
Framingham Heart Study, 30-year follow-up data, discussed extensively in Ravnskov, The Cholesterol Myths, and Kendrick, The Great Cholesterol Con. William Castelli’s admission on saturated fat and serum cholesterol appears in Castelli WP, “Concerning the possibility of a nut...,” Archives of Internal Medicine 152 (1992): 1371–1372.
Multiple Risk Factor Intervention Trial (MRFIT) Research Group, various publications 1982–1996, discussed in Ravnskov, The Cholesterol Myths.
Malcolm Kendrick, The Clot Thickens: The Enduring Mystery of Heart Disease (Columbus Publishing, 2021).
Peter Langsjoen and Alena Langsjoen, “The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10,” BioFactors 18 (2003): 101–111. See also Karl Folkers et al., “Lovastatin decreases coenzyme Q levels in humans,” Proceedings of the National Academy of Sciences 87 (1990): 8931–8934.
Marcoff L, Thompson PD, “The role of coenzyme Q10 in statin-associated myopathy: a systematic review,” Journal of the American College of Cardiology 49 (2007): 2231–2237. Qu H et al., “Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis,” European Journal of Medical Research 23 (2018): 57.
United States Patent 4,929,437, “Coenzyme Q10 with HMG-CoA reductase inhibitors,” issued May 29, 1990. United States Patent 4,933,165, “Coenzyme Q10 with HMG-CoA reductase inhibitors,” issued June 12, 1990 (Michael S. Brown, inventor). Both assigned to Merck & Co.
Malcolm Kendrick, The Great Cholesterol Con, chapter on statin side effects.
Boden WE et al. (COURAGE Trial), “Optimal medical therapy with or without PCI for stable coronary disease,” New England Journal of Medicine 356 (2007): 1503–1516.
Al-Lamee R et al. (ORBITA), “Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial,” The Lancet 391 (2018): 31–40.
Maron DJ et al. (ISCHEMIA), “Initial invasive or conservative strategy for stable coronary disease,” New England Journal of Medicine 382 (2020): 1395–1407.
Coronary Artery Surgery Study (CASS) Principal Investigators, “Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery,” Circulation 68 (1983): 939–950, and related follow-up publications.
Hueb W et al., “Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study II (MASS II),” Circulation 122 (2010): 949–957.
Giorgio Baroldi, “Coronary heart disease: significance of the morphologic lesions,” American Heart Journal 85 (1973): 1–5, and subsequent autopsy series. Discussed in Cowan, Human Heart, Cosmic Heart, and Stephen Hussey, Understanding the Heart (White River Junction, VT: Chelsea Green Publishing, 2022).
Zir LM et al., “Interobserver variability in coronary angiography,” Circulation 53 (1976): 627–632, and subsequent replications.
Blaha MJ et al., “Coronary artery calcium scoring: is it time for a change in methodology?” JACC Cardiovascular Imaging 10 (2017): 923–937. Discussion of the paradox that calcification indicates stability rather than danger appears throughout Kendrick, The Clot Thickens.
SPRINT Research Group, “A randomized trial of intensive versus standard blood-pressure control,” New England Journal of Medicine 373 (2015): 2103–2116. Critique of the unattended BP measurement protocol appears in Kjeldsen SE et al., “Unattended blood pressure measurements in the Systolic Blood Pressure Intervention Trial: implications for entry and achieved blood pressure values compared with other trials,” Hypertension 67 (2016): 808–812.
Diao D et al., “Pharmacotherapy for mild hypertension,” Cochrane Database of Systematic Reviews 8 (2012): CD006742.
Siri-Tarino PW et al., “Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease,” American Journal of Clinical Nutrition 91 (2010): 535–546.
Chowdhury R et al., “Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis,” Annals of Internal Medicine 160 (2014): 398–406.
de Souza RJ et al., “Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies,” BMJ 351 (2015): h3978.
Ramsden CE et al., “Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis,” BMJ 346 (2013): e8707.
Ramsden CE et al., “Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73),” BMJ 353 (2016): i1246.
Nina Teicholz, The Big Fat Surprise: Why Butter, Meat and Cheese Belong in a Healthy Diet (New York: Simon & Schuster, 2014).
James DiNicolantonio, The Salt Fix: Why the Experts Got It All Wrong and How Eating More Might Save Your Life (New York: Harmony Books, 2017).
Mente A et al. (PURE), “Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies,” The Lancet 388 (2016): 465–475.
Kearns CE, Schmidt LA, Glantz SA, “Sugar industry and coronary heart disease research: a historical analysis of internal industry documents,” JAMA Internal Medicine 176 (2016): 1680–1685.
Selhub J et al., “Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis,” New England Journal of Medicine 332 (1995): 286–291 (Framingham data).
Graham IM et al., “Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project,” JAMA 277 (1997): 1775–1781.
Rimm EB et al., “Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women,” JAMA 279 (1998): 359–364.
Lonn E et al. (HOPE-2), “Homocysteine lowering with folic acid and B vitamins in vascular disease,” New England Journal of Medicine 354 (2006): 1567–1577. Stroke as a secondary endpoint: hazard ratio 0.75 (95% CI 0.59–0.97, p=0.03). The primary composite endpoint (cardiovascular death, MI, stroke) did not reach statistical significance.
Bønaa KH et al. (NORVIT), “Homocysteine lowering and cardiovascular events after acute myocardial infarction,” New England Journal of Medicine 354 (2006): 1578–1588. Toole JF et al. (VISP), “Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial,” JAMA 291 (2004): 565–575. Both trials were null for their composite cardiovascular endpoints.
Debreceni B, Debreceni L, “The role of homocysteine-lowering B-vitamins in the primary prevention of cardiovascular disease,” Cardiovascular Therapeutics 32 (2014): 130–138. Discussion of methylation-cycle bioavailability differences between folic acid and methylfolate appears in Scaglione F, Panzavolta G, “Folate, folic acid and 5-methyltetrahydrofolate are not the same thing,” Xenobiotica 44 (2014): 480–488.
George E. Meinig, Root Canal Cover-Up (Bion Publishing, 1998), documenting Weston Price’s twenty-five-year research program, the rabbit-implantation studies, the endocarditis case in which 28 of 30 rabbits died, and the sterilized-powder experiments demonstrating that the toxin remained potent after bacterial removal.
Willershausen I et al., “Association between chronic dental infection and acute myocardial infarction,” Journal of Endodontics 35 (2009): 626–630.
Stephen Hussey, Understanding the Heart: Surprising Insights into the Evolutionary Origins of Heart Disease and Why It Matters (White River Junction, VT: Chelsea Green Publishing, 2022), chapter on dental-cardiac connections.
Louis F. Rose et al., eds., Periodontal Medicine (Hamilton, ON: BC Decker, 2000), cited in Hussey, Understanding the Heart.
Manteuffel-Szoege L, “Remarks on the circulation of the blood following stopping of the heart,” Journal of Cardiovascular Surgery 7 (1966): 201–208. Discussed in Hussey, Understanding the Heart, chapter 6.
Embryological observations on pre-cardiac blood flow are documented in Branko Furst, The Heart and Circulation: An Integrative Model (London: Springer, 2013), and discussed in Cowan, Human Heart, Cosmic Heart.
Yusuf S et al. (CHARM-Preserved), The Lancet 362 (2003): 777–781. Cleland JGF et al. (PEP-CHF), European Heart Journal 27 (2006): 2338–2345. Massie BM et al. (I-PRESERVE), New England Journal of Medicine 359 (2008): 2456–2467. Pitt B et al. (TOPCAT), New England Journal of Medicine 370 (2014): 1383–1392.
Desai AS et al., “2023 JACC Heart Failure Scientific Statement on heart failure with preserved ejection fraction,” JACC Heart Failure (2023).
Langsjoen PH et al., “Statin-associated cardiomyopathy responds to statin withdrawal and administration of coenzyme Q10,” The Permanente Journal 23 (2019): 18.257.
Mortensen SA et al. (Q-SYMBIO), “The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial,” JACC Heart Failure 2 (2014): 641–649.
Gerald H. Pollack, The Fourth Phase of Water: Beyond Solid, Liquid, and Vapor (Seattle: Ebner and Sons Publishers, 2013).
Torrent-Guasp F et al., “The structure and function of the helical heart and its buttress wrapping. I. The normal macroscopic structure of the heart,” Seminars in Thoracic and Cardiovascular Surgery 13 (2001): 301–319, and Torrent-Guasp F et al., “Towards new understanding of the heart structure and function,” European Journal of Cardio-Thoracic Surgery 27 (2005): 191–201.
German clinical literature on strophanthus compiled by Dr. Knut Sroka and Dr. Rolf-Jürgen Petry, archived at strophantus.de and in the Internet Archive. Coal miners data from Professor Kern, 1970s Germany. Berlin hospital twelve-year series and the survey of German physicians documented in “The Gift from Paradise: Strophanthus and the Heart Medicine That Disappeared,” Lies Are Unbekoming, February 4, 2026.
Digitalis Investigation Group, “The effect of digoxin on mortality and morbidity in patients with heart failure,” New England Journal of Medicine 336 (1997): 525–533. Digoxin toxicity hospital visit data from Patel N et al., “Digoxin Toxicity,” in StatPearls (2024).
Thank you, very helpful.